EUVIMEDOpdag EUVIMED
Multizentrische Studie

A Saudi multicenter experience on therapeutic plasma exchange for patients with thrombotic thrombocytopenic purpura: A call for national registry

Osman Radhwi iD, Maha A Badawi iD, Adel Almarzouki, Fakhr Al-Ayoubi iD, Ghada ElGohary iD, Kazi Nur Asfina iD, Abdulrahim Mohammed Basendwah iD, Iman Ayed Alhazmi iD, Eiman A Almahasnah iD, Ahmed AlBahrani iD, Abdulrahman Al Raizah, Ayel Yahya iD and 2 more

Journal of Clinical Apheresis · 2023

DOI: 10.1002/jca.22067 ↗

At a glance

Multizentrische Studie in Journal of Clinical Apheresis, 2023. Written by Osman Radhwi and 13 co-authors. Institution: Department of Hematology, King Abdulaziz University, Jeddah, Saudi Arabia. Major MEDLINE topics: Plasma Exchange, Purpura, Thrombotic Thrombocytopenic. Cited 2 times so far (Crossref); 40 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

The improvement in the clinical care for patients with thrombotic thrombocytopenic purpura (TTP) is evolving, and many efforts are being put to standardize it. Here, we aimed to assess the provided care at a national level and identify deficiencies.

Methods

A national Saudi retrospective descriptive study was carried out at six tertiary referral centers and included all patients who underwent therapeutic plasma exchange (TPE) for the diagnosis of TTP between May 2005, and July 2022. Collected information included demographic data, clinical features on presentation, and the results of laboratory investigations at admission and discharge. In addition, the number of TPE sessions, days till the first session of TPE, usage of immunological agents, and clinical outcomes were all collected.

Results

One hundred patients were enrolled, predominantly female (56%). The mean age was 36.8 years. At diagnosis, 53% of patients showed neurological involvement. The mean platelet count at presentation was 21 × 10 9 /L. All patients had anemia (mean hematocrit 24.2%). Schistocytes were present in the peripheral blood film of all patients. The mean number of TPE rounds was 13 ± 9.3, and the mean days to start TPE since admission for the first episode was 2.5 days. ADAMTS13 level was measured in 48% of patients and was significantly low in 77% of them. Assessing for clinical TTP scores, 83%, 1000%, 64% of eligible patients had an intermediate/high PLASMIC, FRENCH, and Bentley scores, respectively. Caplacizumab was used on only one patient, and rituximab was administered to 37% of patients. A complete response for the first episode was achieved in 78% of patients. The overall mortality rate was 25%. Neither time to TPE, the use of rituximab or steroid affected survival.

Conclusions

Our study shows an excellent response to TPE with a survival rate approximate to the reported international literature. We observed a deficiency in using validated scoring systems in addition to confirming the disease by ADAMTS13 testing. This emphasizes the need for a national registry to facilitate proper diagnosis and management of this rare disorder.

Subjects

MeSH terms (MEDLINE)

Plasma ExchangePurpura, Thrombotic ThrombocytopenicHumansFemaleAdultMaleRituximabRetrospective StudiesSaudi ArabiaADAMTS13 ProteinRegistries

Author keywords

ADAMTS13BentleyPLASMICapheresiscaplacizumabplasma exchangerituximab

Substances

RituximabADAMTS13 Protein

Authors and institutions

  • Department of Hematology, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Hematology Research Unit, King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Blood Transfusion Services Unit, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
  • Department of Cardiac Sciences, King Fahad Cardiac Center, King Khalid University Hospital, King Saud University, Riyadh, Kingdom of Saudi Arabia.
  • Department of Adult Hematology/Oncology, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.
  • Hematology and Oncology Division, Department of Medicine, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.

ORCID profiles: Osman Radhwi, Maha A Badawi, Fakhr Al-Ayoubi, Ghada ElGohary, Kazi Nur Asfina, Abdulrahim Mohammed Basendwah, Iman Ayed Alhazmi, Eiman A Almahasnah, Ahmed AlBahrani, Ayel Yahya, Salwa Hindawi

Cite

APA

Radhwi, O., Badawi, M. A., Almarzouki, A., Al-Ayoubi, F., ElGohary, G., Asfina, K. N., Basendwah, A. M., Alhazmi, I. A., Almahasnah, E. A., AlBahrani, A., Raizah, A. A., Yahya, A., Alshahrani, K., & Hindawi, S. (2023). A Saudi multicenter experience on therapeutic plasma exchange for patients with thrombotic thrombocytopenic purpura: A call for national registry. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.22067

Vancouver

Radhwi O, Badawi MA, Almarzouki A, Al-Ayoubi F, ElGohary G, Asfina KN, et al. A Saudi multicenter experience on therapeutic plasma exchange for patients with thrombotic thrombocytopenic purpura: A call for national registry. Journal of Clinical Apheresis. 2023. doi:10.1002/jca.22067

BibTeX
@article{Radhwi2023,
  author = {Radhwi, Osman and Badawi, Maha A and Almarzouki, Adel and Al-Ayoubi, Fakhr and ElGohary, Ghada and Asfina, Kazi Nur and Basendwah, Abdulrahim Mohammed and Alhazmi, Iman Ayed and Almahasnah, Eiman A and AlBahrani, Ahmed and Raizah, Abdulrahman Al and Yahya, Ayel and Alshahrani, Khadeja and Hindawi, Salwa},
  title = {A Saudi multicenter experience on therapeutic plasma exchange for patients with thrombotic thrombocytopenic purpura: A call for national registry},
  journal = {Journal of Clinical Apheresis},
  year = {2023},
  doi = {10.1002/jca.22067}
}
Start for free →